累计签到:104 天
连续签到:1 天
[LV.6]超级爱粉
问题1,原因我上面已经说过了,相关临床对比数据请查阅文献1、文献2;
问题2,我建议的是培美化疗方案联合贝伐单抗,单培美方案对抑制胸水信心不足;
问题3,对于未治疗的局部晚期或转移晚期患者,ctDNA检测结果具有较高的参考价值。
参考文献:
1、《Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy》;
2、《Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)》;
|
|
|
|